Literature DB >> 21487529

Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literature.

Nicole M Agostino1, Basil Ahmed, Dan Popescu, Shereen Gheith.   

Abstract

Myelodysplastic syndrome (MDS) with an isolated deletion of the long arm of chromosome 5 (5q- syndrome) is a distinct subtype of MDS with an indolent course that rarely transforms to acute leukemia. Deletion of the long arm of chromosome 5 has also been reported in rare cases of de novo B-lymphoblastic leukemia. We present two cases of 5q- syndrome with a similar and unusual course of transformation to lymphoblastic leukemia while on Lenalidomide. These two patients achieved an initial response; however, later acquired a second cytogenetic abnormality, became refractory to treatment and evolved into acute leukemia. At the time of transformation, both patients had recurrence of the 5q- abnormality. Review of the literature and the mechanisms of transformation of the 5q-syndrome into an acute leukemia are discussed. Although the relationship between the events in our cases remains unclear, the intriguing similarity between the two cases raises a question whether immune modulators can alter the natural course of MDS. To our knowledge, no similar cases were previously reported in the literature.

Entities:  

Keywords:  5q- syndrome; Myelodysplastic; acute lymphoblastic leukemia; lenalidomide; syndrome

Mesh:

Year:  2011        PMID: 21487529      PMCID: PMC3071666     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  12 in total

1.  Unexpected cytogenetic finding in acute lymphoblastic leukemia: a case of del(5q) with a cryptic t(12;21).

Authors:  Sarah T South; J Kimble Frazer; Arthur R Brothman; Zhong Chen
Journal:  Cancer Genet Cytogenet       Date:  2006-07-15

Review 2.  5q- anomaly in acute lymphoblastic leukemia.

Authors:  R Berger; M Le Coniat; J Derré
Journal:  Cancer Genet Cytogenet       Date:  1992-07-15

3.  World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.

Authors:  Paolo Bernasconi; Catherine Klersy; Marina Boni; Paola M Cavigliano; Silvia Calatroni; Ilaria Giardini; Barbara Rocca; Rita Zappatore; Marilena Caresana; Irene Dambruoso; Mario Lazzarino; Carlo Bernasconi
Journal:  Br J Haematol       Date:  2007-05       Impact factor: 6.998

4.  Efficacy of lenalidomide in myelodysplastic syndromes.

Authors:  Alan List; Sandy Kurtin; Denise J Roe; Andrew Buresh; Daruka Mahadevan; Deborah Fuchs; Lisa Rimsza; Ruth Heaton; Robert Knight; Jerome B Zeldis
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

5.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

Review 6.  Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature.

Authors:  Norihide Sato; Tomonori Nakazato; Masahiro Kizaki; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

7.  Acute lymphoblastic leukemia with hypereosinophilia: report of a case with 5q deletion and review of the literature.

Authors:  Tung T Wynn; Nyla A Heerema; Sue Hammond; Mark Ranalli; Samir B Kahwash
Journal:  Pediatr Dev Pathol       Date:  2003 Nov-Dec

8.  Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Authors:  Martin Jädersten; Leonie Saft; Andrea Pellagatti; Gudrun Göhring; James S Wainscoat; Jacqueline Boultwood; Anna Porwit; Brigitte Schlegelberger; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

9.  Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.

Authors:  Virginie Eclache; Anna Da Rocha; Génevieve Le Roux; Pierre Fenaux
Journal:  Haematologica       Date:  2008-02       Impact factor: 9.941

10.  WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

Authors:  M M Patnaik; T L Lasho; C M Finke; N Gangat; D Caramazza; S G Holtan; A Pardanani; R A Knudson; R P Ketterling; D Chen; J D Hoyer; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2010-05-20       Impact factor: 12.883

View more
  6 in total

1.  Acquired EVI1 rearrangement involved in the transformation from 5q- syndrome to pre-B lymphocytic leukemia in a Chinese patient.

Authors:  Dandan Liu; Suning Chen; Jinlan Pan; Mingqing Zhu; Ni Wu; Feng Zhu; Zixing Chen
Journal:  Int J Hematol       Date:  2012-10-09       Impact factor: 2.490

2.  Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.

Authors:  Preetesh Jain; Guilin Tang; Sergej N Konoplev; Rashmi Kanagal-Shamanna; Sa A Wang; Naveen Pemmaraju; Naval Daver; Zeev Estrov
Journal:  Am J Hematol       Date:  2016-01-11       Impact factor: 10.047

3.  RARS with fibrosis and del(20q) transformed into ALL.

Authors:  Sandra S Rohr; Luís Arthur Flores Pelloso; Aline dos Santos Borgo; João Garibaldi de Rezende; Maria Regina Regis Silva; Mihoko Yamamoto; Maria de Lourdes L F Chauffaille
Journal:  Med Oncol       Date:  2012-07-04       Impact factor: 3.064

4.  A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.

Authors:  Ranjit Nair; Shereen Gheith; Dan Popescu; Nicole M Agostino
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

5.  Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.

Authors:  Ahmad Alhuraiji; Kiran Naqvi; Yang O Huh; Coty Ho; Srdan Verstovsek; Prithviraj Bose
Journal:  Clin Case Rep       Date:  2017-12-06

6.  Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.

Authors:  Sebastian Burgos; Guillermo Montalban-Bravo; Lucia Fuente; Elias J Jabbour; Rashmi Kanagal-Shamanna; Kelly A Soltysiak; Guillermo Garcia-Manero; Maria J Mela-Osorio
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.